Daxor (DXR) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual Meeting scheduled for June 24, 2025, at Nasdaq offices in New York, with voting on director elections and auditor ratification.
Shareholders of record as of May 19, 2025, are eligible to vote, with one vote per share; 4,962,245 shares outstanding.
Board recommends voting for all director nominees and for ratification of Bush & Associates, CPA as independent auditor.
Voting matters and shareholder proposals
Proposal 1: Election of six directors for one-year terms; plurality vote required.
Proposal 2: Ratification of Bush & Associates, CPA as independent registered public accounting firm for 2025; majority vote required.
Shareholder proposals for the 2026 meeting must be received by February 21, 2026, for inclusion.
Board of directors and corporate governance
Board consists of six members, four of whom are independent; no lead independent director.
Board is responsible for management oversight and has an audit committee; no standing compensation or nominating committee due to controlled company status.
Directors and officers serve annual terms; full Board handles nominations and compensation.
Board members are encouraged to attend the annual meeting, with teleconference attendance permitted.
Latest events from Daxor
- Rapidly growing with FDA-cleared analyzers, proven clinical impact, and strong recurring revenue.DXR
Corporate presentation23 Mar 2026 - Direct blood volume analysis drives clinical impact and commercial growth, with 45% revenue increase.DXR
IAccess Alpha Virtual Best Ideas Spring Investment Conference 202610 Mar 2026 - Operating revenue up 45% and net asset value per share climbs to $9.07, signaling strong growth.DXR
Q4 20259 Mar 2026 - Achieved strong revenue growth, cash flow break-even, and poised for major product launches.DXR
Q4 202424 Dec 2025 - Annual meeting to elect six directors and ratify Citrin Cooperman, LLP as auditor for 2024.DXR
Proxy Filing2 Dec 2025 - Revenue surged 116.5% as new FDA-cleared analyzers and recurring kit sales drive growth.DXR
Corporate Presentation24 Sep 2025 - Net assets increased year-over-year, driven by higher operating division revenue and improved results.DXR
Q2 202413 Jun 2025